Elena N. Yushchuk

Elena N. Yushchuk

Auto-generated profile, based on publicly available information

Elena N. Yushchuk

Russian University of Medicine

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2021 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
ETElena V. Tsyganova
Elena V. Tsyganova
NGNataliia V. Glukhoedova
Nataliia V. Glukhoedova
AZAleksandra S. Zhilenkova
Aleksandra S. Zhilenkova
TFTatiana I. Fedoseeva
Tatiana I. Fedoseeva
EIElena N. Iushchuk
Elena N. Iushchuk
NSNatalia S. Smetneva
Natalia S. Smetneva
The article provides an overview of current information on the pathogenesis of COVID-19 and organ-specific lesions developing in this disease. The data on inflammation and its biochemical markers, on the features of coagulopathy, endothelial damage and microthrombosis are presented in detail. Particular attention is paid to the role of receptors for angiotensin converting enzyme type 2 and transmembrane serine protease type 2 in the development of organ-specific lesions in COVID-19. The pathogenesis of damage to the cardiovascular system is considered in detail with the presentation of data from foreign literature on changes in the myocardium and the author's results of transthoracic echocardiographic examination in patients who have undergone COVID-19.

16 September 2019 in Obesity and metabolism
Verified
Journal Article
Open access
ESElena Y. Shupenina
Elena Y. Shupenina
EYElena N. Yushchuk
Elena N. Yushchuk
YVYury A. Vasyuk
Yury A. Vasyuk
SYSvetlana V. Yureneva
Svetlana V. Yureneva
ADAnastasia V. Dubrovina
Anastasia V. Dubrovina
BACKGROUND: Obesity is a metabolic disorder that becomes epidemic. Visceral adiposity increases the risk of arterial hypertension, diabetes mellitus and other comorbidities. According to this, the main aim of obesity treatment is not only a weight loss but also a decrease of the risk of comorbidities. AIMS: to assess the efficiency and safety of sibutramine in patients with obesity and arterial hypertension, to evaluate the drug influence on epicardial fat thickness. MATERIALS AND METHODS: 57 patients aged 35-60 with obesity and arterial hypertension were included in the study. All patients at the beginning and after 7 months of follow-up underwent complex examination including anthropometric measurement, ECG, office and ambulatory blood pressure measurement, echocardiography. Patients with controlled arterial hypertension were included. During the first month of follow-up patients were given general weight loss recommendations. Then sibutramine was added. Control visits to assess efficiency and safety of drug treatment were held after 1 and 6 months of follow-up. RESULTS: Women predominated among the study participants. Visceral adiposity was approved by anthropometric measurements among all patients. Most patients had impaired left ventricle geometry: concentric remodeling or hypertrophy. During the first month of follow-up the weight loss was mild: 2 kg (less than 2%) in average. Sibutramine for 1 month the weight loss increased: 3.7 kg (more than 2%) in average. After 6 months of drug administration the weight loss of patients consisted 8.6 kg (6.2%) in average. According to echocardiography results indexed mass of LV myocardium decreased in all patients more significantly in women. Also in this group of patients significant decrease of epicardial fat thickness was revealed. Adverse events of sibutramine were revealed in 26.3% of patients. The most frequent were constipation (12.3%) and dry mouth (10.6%). The severity of symptoms persisted for 1 month and then decreased, additional therapy was not required. CONCLUSIONS: Sibutramine treatment of obesity promotes effective weight loss, influences the adipose tissue distribution, decreases the progress of associated comorbidities. Sibutramine is an effective and safe drug that can be used in patients with visceral adiposity and controlled arterial hypertension.

16 January 2023 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
ISI A Sadulaeva
I A Sadulaeva
EYE N Yushchuk
E N Yushchuk
LKL F Khalikova
L F Khalikova
OKO V Krikunova
O V Krikunova
OTO S Trofimenko
O S Trofimenko
EME G Medvedeva
E G Medvedeva
Aim. To investigate the possibility of preclinical detection of liver damage in patients with hypertension and obesity. Materials and methods. The study included 168 patients with hypertension aged 30 to 60 years. All patients underwent general clinical and laboratory-instrumental examination, including ultrasound of the abdominal organs with Doppler assessment of blood flow and determination of markers such as ALT, AST, TG, lipid profile indicators at inclusion, after a month, three months and nine months. Results. Depending on the presence of obesity, all patients with hypertension were divided into two groups. Obese patients had a statistically significant increase in office blood pressure, FSI, the ratio of TG and LDL-C to HDL-C, a more significant higher average levels of glucose, TG and ALT levels, as well as impaired hepatic blood flow according to ultrasound. Conclusion. Indicators of FSI, ALT/AST ratio, ratio of TG and LDL-С to HDL-C as well as assessment of hepatic blood flow indicators can be used for early diagnosis of nonalcoholic fatty liver disease, as they predict liver steatosis.

8 September 2019 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
YVYu. A. Vasyuk
Yu. A. Vasyuk
ESE. Yu. Shupenina
E. Yu. Shupenina
EYE. N. Yuschuk
E. N. Yuschuk
GNG. A. Namazova
G. A. Namazova
ЮВЮ. А. Васюк
Ю. А. Васюк
Aim. To assess the effect of azilsartan/chlortalidone and irbesartan/hydrochlorothiazide fixed combinations on office, daily peripheral and central blood pressure (BP), daily parameters of aortic stiffness and structural and functional state of the left ventricle in patients with arterial hypertension (AH) and obesity.Material and methods. The study included 46 patients with hypertension and obesity aged 35 to 55 years. In the beginning of the study and after 6 months of treatment with azilsartan/chlortalidone (AZL/C) or irbesartan/hydrochlorothiazide (IRB/H) all patients underwent a comprehensive clinical and instrumental and laboratory examination, including a general examination with anthropometric measurements, office measurement of BP, electrocardiography, echocardiography, 24-hour BP monitoring with analysis of central BP and the main parameters of aortic stiffness, biochemical blood tests.Results. Long-term use of two fixed combinations of sartan and diuretic was accompanied by a significant decrease of office and daily BP. However, in the AZL/С use, this change was more pronounced than in the IRB/H. Also, in the AZL/H group, a significantly larger number of patients reach a normalization of 24-hour BP profile. Both studied drugs significantly reduced central BP, which indicates their positive effect on aortic stiffness. However, a significant change in the daily pulse wave velocity determined by the Vasotens system was not detected. During therapy, in both groups, a decrease in left ventricular myocardial mass indexed by body surface area was revealed. It was more noticeable in the AZL/H group and when height indexed2,7. In both groups, an insignificant decrease in creatinine level and an increase in glomerular filtration rate, more noticeable with the administration of AZL/H, were noted. There were no significant fluctuations in the level of uric acid and patients with AH and obesity.Conclusion. According to studies, AH in obese patients is less well controlled than in patients with normal body weight. AZL/H and IRB/H are effective and safe drugs for the treatment of AH in obese patients. However, long-term treatment of AZL/H allows reaching a more pronounced decrease in peripheral and central BP, improving the structural and functional state of the left ventricular myocardium in comparison with IRB/H.

1 January 2020 in Immunologiya
Verified
Journal Article
Closed access
IBI.P. Balmasova
I.P. Balmasova
VTV.N. Tsarev
V.N. Tsarev
EYE.N. Yushchuk
E.N. Yushchuk
ADA.S. Dorovskikh
A.S. Dorovskikh
EME.S. Malova
E.S. Malova
SAS.D. Arutyunov
S.D. Arutyunov

11 October 2023 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
EYElena N. Yushchuk
Elena N. Yushchuk
EMElizaveta G. Medvedeva
Elizaveta G. Medvedeva
DFDaria A. Filonenko
Daria A. Filonenko
SISvetlana V. Ivanova
Svetlana V. Ivanova
LZLiudmila Zhukova
Liudmila Zhukova
DSDaria A. Sapunova
Daria A. Sapunova
Background. Modern breast cancer chemotherapy regimens (BC) consider individual patient parameters and ranges of cardiotoxic doses. However, clinicians often record clinical and laboratory-instrumental signs of cardio- and vasculotoxicity in patients, which emphasizes the high importance of searching for markers of early toxic response. Aim. To study the characteristics of the response of arterial stiffness on the background of anthracycline-containing chemotherapy to determine potential markers of vasculotoxicity in BC patients. Materials and methods. 20 women with a BC were included. The patients received 4 cycles of chemotherapy in the doxorubicin + cyclophosphane (AC) regimen with an interval of 23 weeks, then they were injected with paclitaxel weekly for 12 injections, or docetaxel once every 3 weeks. All patients underwent TTE, arterial stiffness determination by the "gold standard" method and using volumetric sphygmography before the start of treatment, after the completion of the anthracycline component and after the end of taxanes. Results. The average age of the patients was 45.55.31 years. After completing the course of anthracyclines, there was a significant increase in heart rate (from 65.69.3 to 73.310.1 beats/min.), a decrease in SBP (from 122.69.9 to 116.512.3 mmHg) and DBP (from 78.98.5 to 76.28.6 mmHg), a decrease in carotid femoral pulse wave velocity (cfPWV) (from 9.321.41 to 7.851.57 m/s), CAVI index on the left (from 6.780.81 to 6.50.88), the velocity of the cardio-ankle pulse wave on the right and left (from 6.70.6 to 6.50.7 m/s; from 7.00.6 to 6.30.8 m/sc, respectively). After the completion of the taxane, there was a tendency to increase these indicators, however, they remained significantly lower compared to the values before the start of treatment. Conclusion. A comparative analysis of arterial stiffness indicators at different stages of chemotherapy showed a more pronounced reaction of cfPWV, CAVI, cardio-ankle pulse wave to the administration of anthracyclines, which presumably may be associated with concomitant hemodynamic restructuring.